Health ❯ Medicine ❯ Pharmaceuticals

Drug Development

Clinical Trials Obesity Treatments Alzheimer's Disease Weight Loss Drugs Cholesterol Management Obesity Treatment Donidalorsen Existing Drugs FDA Approval Cancer Treatments Inflammatory Bowel Disease Weight Loss Treatments Pain Medication Muscle-Activating Compounds ERR Protein Activation Semaglutide Research and Development Antiviral Drugs Amylyx Pharmaceuticals Drug Withdrawal Regulatory Updates Regulatory Approval Chemotherapeutic Drugs Gepotidacin Synthetic Biology Sildenafil Gleevec Synthesis Methods Malaria Treatment Sarepta Therapeutics COPD Treatment Quantum Computing in Medicine Experimental Drugs Leucovorin Bradykinin B2 Receptor Antagonists Synthetic Proteins Oncology Weight Loss Medications Epilepsy Treatment Cholesterol Medications Cancer Therapies Novo Nordisk Psoriasis Treatment Phage Therapy Acoziborole Winthrop Expanded Access Programs Orphan Drugs Rentosertib Skin Cancer IMVT-1402 Compassionate Use RAS Inhibitors Daraxonrasib Botulinum Toxin AI-Generated Drugs AI-Designed Drugs Aging Research Hemophilia Treatments AI in Medicine

AI-Designed Drug Rentosertib Lowers Biological-Age Signals in Small Trial

The results could point to a druggable way to alter biological aging if larger trials confirm the biomarker changes.

Alumis Shares Plunge After Phase 2b Lupus Trial Misses Primary Goal

Eli Lilly Opens Limited Early Access to Experimental Obesity Drug Retatrutide

Lilly Will Seek FDA Approval for Retatrutide in Q1 2027 After Two More Positive Phase 3 Trials

Immunovant Shares Surge on Strong Rheumatoid Arthritis Data for IMVT-1402

FDA Grants Orphan Drug Status to Immutep’s Efti for Soft Tissue Sarcoma

Xenon to Present Topline X-TOLE2 Phase 3 Results in Focal Onset Seizures at 8 A.M. ET Today

EMA Backs Single-Dose Acoziborole for Gambiense Sleeping Sickness Outside EU

Novo’s Triple-Hormone Obesity Drug UBT251 Hits 19.7% Mean Weight Loss in China Phase 2

Pfizer’s Monthly Obesity Shot Shows Mid-Stage Gains With Up to 12.3% Weight Loss

Lilly and Nimbus Strike Multi-Year AI Deal for Oral Obesity Drugs

Takeda’s AI-Assisted Psoriasis Pill Succeeds in Phase 3, Outperforms Otezla

Sanofi Secures Global Rights to ADEL’s Alzheimer’s Antibody in Deal Worth Up to $1.04 Billion

Pharvaris’ Oral HAE Drug Deucrictibant Delivers Rapid Relief in Pivotal Phase 3

Merck to Buy Cidara for $9.2 Billion to Secure Long-Acting Flu Drug

Merck’s Oral PCSK9 Pill Matches Injectables in Phase 3, Setting Up 2026 FDA Bid

FDA Reapproves GSK’s Blenrep for Multiple Myeloma in Narrow Combination Use

Novartis Ianalumab Meets Efficacy and Safety Goals in Phase 3 Sjögren’s Trials

GSK Closes $12 Billion Licensing Pact for Hengrui’s COPD Therapy and 11 Preclinical Assets

Cancer Drugs Reverse Alzheimer’s Pathology in Mice, Advance to Clinical Trials